ESC Premium Access

CSK9 inhibitors and cardiovascular outcomes – Represented in New England Journal of Medicine by the FOURIER and SPIRE trials.

Congress Session

About the speaker

Professor Marc Sabatine

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
16 presentations
1 follower

3 more presentations in this session

Bioresorbable vascular scaffolds for PCI – Represented in New England Journal of Medicin by the ABSORB III and AIDA trials.

Speaker: Doctor J. Wykrzykowska (Groningen, NL)


ICD implantation for non-ischaemic cardiomyopathy – Represented in New England Journal of Medicine by the DANISH trial.

Speaker: Professor L. Kober (Copenhagen, DK)


Prevention of recurrent venous thromboembolism – Represented in New England Journal of Medicine by several trials, including EINSTEIN, AMPLIFY, WARFASA, Hokusai-VTE, and others.

Speaker: Doctor J. Weitz (Hamilton, CA)


Access the full session

Highlights from the New England Journal of Medicine: editors’ choice

Speakers: Professor M. Sabatine, Doctor J. Wykrzykowska, Professor L. Kober, Doctor J. Weitz

About the event



26 August - 30 August 2017

Sessions Presentations

Related content

Open Access

Live discussion: The new ESC Heart Failure guidelines & potassium binding: What will change?

30 August 2021

ESC Premium Access

Cardiovascular benefit of lowering LDL-C below 1 mmol/L (40 mg/dl)

28 August 2021

Open Access

New recommendations for the treatment of HFrEF.

27 August 2021

This platform is supported by

logo Novo Nordisk